Corcept Therapeutics Incorporated

DB:HTD Stock Report

Market Cap: €6.9b

Corcept Therapeutics Valuation

Is HTD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HTD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€34.58
Fair Value
89.3% overvalued intrinsic discount
4
Number of Analysts

Below Fair Value: HTD (€65.48) is trading above our estimate of fair value (€34.58)

Significantly Below Fair Value: HTD is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HTD?

Key metric: As HTD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HTD. This is calculated by dividing HTD's market cap by their current earnings.
What is HTD's PE Ratio?
PE Ratio50.7x
EarningsUS$140.49m
Market CapUS$7.13b

Price to Earnings Ratio vs Peers

How does HTD's PE Ratio compare to its peers?

The above table shows the PE ratio for HTD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22x
DMP Dermapharm Holding
23.2x17.3%€2.1b
MRK Merck KGaA
22.6x10.2%€60.9b
PSG PharmaSGP Holding
17.9x14.1%€335.7m
1SXP SCHOTT Pharma KGaA
24.2x13.9%€3.6b
HTD Corcept Therapeutics
50.7x37.1%€7.1b

Price-To-Earnings vs Peers: HTD is expensive based on its Price-To-Earnings Ratio (50.7x) compared to the peer average (22x).

Price to Earnings Ratio vs Industry

How does HTD's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
HTD 50.7xIndustry Avg. 22.1xNo. of Companies9PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HTD is expensive based on its Price-To-Earnings Ratio (50.7x) compared to the European Pharmaceuticals industry average (22.1x).

Price to Earnings Ratio vs Fair Ratio

What is HTD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HTD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio50.7x
Fair PE Ratio29x

Price-To-Earnings vs Fair Ratio: HTD is expensive based on its Price-To-Earnings Ratio (50.7x) compared to the estimated Fair Price-To-Earnings Ratio (29x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HTD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€65.48
€84.98
+29.8%
27.8%€125.18€64.51n/a4
Feb ’26€64.34
€84.81
+31.8%
27.8%€124.93€64.39n/a4
Jan ’26€50.54
€70.92
+40.3%
6.0%€75.74€63.44n/a5
Dec ’25€54.32
€68.86
+26.8%
6.0%€73.55€61.60n/a5
Nov ’25€43.31
€68.86
+59.0%
6.0%€73.55€61.60n/a5
Oct ’25€41.09
€60.54
+47.3%
17.6%€69.86€40.30n/a5
Sep ’25€31.74
€55.04
+73.4%
26.0%€72.03€35.09n/a5
Aug ’25€34.68
€55.04
+58.7%
26.0%€72.03€35.09n/a5
Jul ’25€29.91
€46.39
+55.1%
30.0%€65.81€32.67n/a5
Jun ’25€28.51
€42.13
+47.8%
28.2%€65.28€32.41n/a5
May ’25€21.84
€39.98
+83.1%
21.9%€56.99€32.70n/a5
Apr ’25€23.20
€39.72
+71.2%
21.9%€56.61€32.48n/a5
Mar ’25€22.20
€39.72
+78.9%
21.9%€56.61€32.48n/a5
Feb ’25€19.70
€33.85
+71.8%
32.5%€56.05€21.13€64.346
Jan ’25€29.60
€34.01
+14.9%
18.6%€45.96€24.82€50.546
Dec ’24€23.20
€34.35
+48.1%
18.6%€46.64€25.18€54.326
Nov ’24€26.00
€32.23
+23.9%
19.9%€44.91€24.58€43.316
Oct ’24€31.00
€30.93
-0.2%
20.6%€43.97€24.07€41.096
Sep ’24€30.80
€30.93
+0.4%
20.6%€43.97€24.07€31.746
Aug ’24€22.80
€28.62
+25.5%
20.9%€41.06€23.33€34.686
Jul ’24€20.40
€28.62
+40.3%
20.9%€41.06€23.33€29.916
Jun ’24€21.20
€28.62
+35.0%
20.9%€41.06€23.33€28.516
May ’24€20.20
€26.97
+33.5%
23.5%€40.32€18.33€21.847
Apr ’24€19.75
€28.39
+43.8%
25.2%€40.56€18.44€23.205
Mar ’24€18.42
€29.07
+57.8%
25.2%€41.27€18.76€22.205
Feb ’24€21.63
€32.46
+50.1%
16.2%€41.76€26.58€19.705
Analyst Price Target
Consensus Narrative from 4 Analysts
€84.97
Fair Value
22.9% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/08 12:19
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Corcept Therapeutics Incorporated is covered by 22 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
David BuckB. Riley Securities, Inc.
Edward NashCanaccord Genuity